These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 30897608)
1. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. Voeller J; Sondel PM J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608 [TBL] [Abstract][Full Text] [Related]
2. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024 [TBL] [Abstract][Full Text] [Related]
3. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105 [TBL] [Abstract][Full Text] [Related]
6. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Parsons K; Bernhardt B; Strickland B Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066 [TBL] [Abstract][Full Text] [Related]
7. Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Castel V; Segura V; Cañete A Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409 [TBL] [Abstract][Full Text] [Related]
8. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Perez Horta Z; Goldberg JL; Sondel PM Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082 [TBL] [Abstract][Full Text] [Related]
9. The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL). Rovigatti U Cancer Lett; 2021 Apr; 503():220-230. PubMed ID: 33271265 [TBL] [Abstract][Full Text] [Related]
10. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
12. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106 [TBL] [Abstract][Full Text] [Related]
13. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. Ahmed M; Cheung NK FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643 [TBL] [Abstract][Full Text] [Related]
14. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106 [TBL] [Abstract][Full Text] [Related]
15. Disialoganglioside directed immunotherapy of neuroblastoma. Modak S; Cheung NK Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560 [TBL] [Abstract][Full Text] [Related]
16. Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model. van den Bijgaart RJE; Kroesen M; Brok IC; Reijnen D; Wassink M; Boon L; Hoogerbrugge PM; Adema GJ Oncoimmunology; 2020 Sep; 9(1):1817653. PubMed ID: 33457098 [TBL] [Abstract][Full Text] [Related]
17. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879 [TBL] [Abstract][Full Text] [Related]
18. State of the art in immunotherapy of neuroblastoma. Jabbari P; Hanaei S; Rezaei N Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. Fukuda M; Horibe K; Furukawa K Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]